SCHEMBL6843706

SCHEMBL6843706

CCCC(CCC)C(=O)N[C@@H](C)C(=O)NCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.59
HDAC3 O15379 2/20 0.56
HDAC4 P56524 2/20 0.56
HDAC1 Q13547 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC8 Q9BY41 2/20 0.56
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
KMT2A Q03164 1/20 0.51
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
LTA4H P09960 2/20 0.48
MME P08473 2/20 0.48
ALDH1A1 P00352 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25214759 0.82 MMP8 (0.63) MMP8CA1CA2KMT2AMAPT
SCHEMBL25214750 0.82 MMP8 (0.63) MMP8CA1CA2KMT2AMAPT
SCHEMBL25240460 0.82 MMP8 (0.63) MMP8CA1CA2KMT2AMAPT
SCHEMBL20152030 0.81 CA1 (0.57) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL24347008 0.81 MMP8 (0.63) MMP8CA1CA2KMT2AMAPT
SCHEMBL24347010 0.81 MMP8 (0.63) MMP8CA1CA2KMT2AMAPT
SCHEMBL6814514 0.80 CA12 (0.64) MMP8CA1CA2KMT2AMAPT
SCHEMBL6813286 0.80 CA12 (0.64) MMP8CA1CA2KMT2AMAPT
SCHEMBL993570 0.80 CA12 (0.64) MMP8CA1CA2KMT2AMAPT
SCHEMBL19152432 0.80 MAPT (0.72) MMP8KMT2AMAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176463-A1 Immediate release formulation of n-(2-propylpentanoyl)glycinamide YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-09-09 US claimed
WO-2004071424-A2 IMMEDIATE RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL)GLYCINAMIDE TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2004-08-26 WO claimed
EP-0659174-B1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RES DEV CO (IL) 1999-02-10 EP claimed
US-5585358-A ANTIEPILEPTIC AGENTS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; DYSKINESIA; ANTIISCHEMIC AGENTS YISSUM RESEARCH DEVELOPMENT CORPORATION OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1996-12-17 US claimed
EP-0659174-A4 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS. YISSUM RES DEV CO (IL) 1995-09-27 EP claimed
EP-0659174-A1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-06-28 EP claimed
WO-1995001956-A1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-01-19 WO claimed
US-20040175423-A1 Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-09-09 US disclosed
US-20040176463-A1 Immediate release formulation of n-(2-propylpentanoyl)glycinamide YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-09-09 US disclosed
EP-0659174-B1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RES DEV CO (IL) 1999-02-10 EP disclosed
US-5585358-A ANTIEPILEPTIC AGENTS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; DYSKINESIA; ANTIISCHEMIC AGENTS YISSUM RESEARCH DEVELOPMENT CORPORATION OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1996-12-17 US disclosed
EP-0659174-A4 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS. YISSUM RES DEV CO (IL) 1995-09-27 EP disclosed
EP-0659174-A1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-06-28 EP disclosed
WO-1995001956-A1 DERIVATIVES OF VALPROIC AND 2-VALPROENOIC ACID AMIDES AND USE AS ANTICONVULSANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176463-A1 Immediate release formulation of n-(2-propylpentanoyl)glycinamide CACNA1E, GRIK1, GRIN2D MMP8 2148/4885HDAC3 25/4885HDAC4 255/4885
US-20040175423-A1 Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds CACNA1E, GRIN2C, GRIN2D MMP8 3113/4885HDAC3 46/4885HDAC4 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.